## Biological Product Information

<table>
<thead>
<tr>
<th>Section 7:</th>
<th>Biological Product Information</th>
<th>Standard #: 07.320</th>
</tr>
</thead>
<tbody>
<tr>
<td>Created by:</td>
<td>Province-wide Immunization Program Standards and Quality</td>
<td></td>
</tr>
<tr>
<td>Approved by:</td>
<td>Province-wide Immunization Program Standards and Quality</td>
<td></td>
</tr>
<tr>
<td>Approval Date:</td>
<td>January 27, 2012</td>
<td>Revised: February 1, 2016</td>
</tr>
</tbody>
</table>

### Td Adsorbed®

- **Manufacturer**: Sanofi Pasteur Limited
- **Biological Classification**: Inactivated

### Indications for Provincially Funded Vaccine

- Primary or reinforcing immunization of individuals 18 years of age and older, when acellular pertussis and polio vaccine are not indicated
  - **Note**: To determine tetanus-diphtheria containing vaccine of choice for HSCT/SOT individuals, refer to Transplant Guideline #08.304.
  - Individuals who sustain a tetanus prone wound need to have their tetanus immunization history assessed (Tetanus Prevention, Prophylaxis and Wound/Injury Management Standard # 08.400)

### Schedule

**Primary vaccine series:**
- Dose 1 – day 0
- Dose 2 – 4 to 8 weeks after dose 1
- Dose 3 – 6 to 12 months after dose 2

Adults receiving a primary series of Td should receive one dose of dTap to replace one dose of Td in the series.

**Reinforcing Doses:**
- Reinforcing doses are recommended at 10-year intervals.
- Individuals presenting for a Td booster who have not received a dose of acellular pertussis containing vaccine as an adult should be given a dose of dTap vaccine regardless of the interval since their last tetanus-diphtheria containing vaccine. See Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine Biological Page (#07.210) for detailed eligibility for dTap vaccine.
- For wound management purposes, shorter intervals may be recommended (Tetanus Prevention, Prophylaxis and Wound/Injury Management Standard # 08.400)

### Preferred Use

- N/A

### Dose

- 0.5 mL

### Route

- IM

### Contraindications/Precautions

#### Contraindications:

- Known severe hypersensitivity to any component of the vaccine.
- Anaphylactic or other allergic reaction to a previous dose of vaccine containing tetanus and diphtheria toxoids.

#### Precautions:

- If Guillain-Barré Syndrome (GBS) occurred within 6 weeks of immunization
### Possible Reactions

| Common: | Tenderness, redness and swelling are the most common reactions and are generally mild and transient in duration. | Following reinforcing doses, local erythema and swelling are not uncommon. | The most frequent systemic reactions are fever, chills and sore or swollen joints. |
| Rare: | Generalized urticaria, anaphylaxis, hypotension and neurological complications have been reported but are rare. | Persistent nodules at the site of injection may occur. | Arthus-type sensitivity may occur. | As with any immunization, unexpected or unusual side effects can occur. Refer to the product monograph for more detailed information. |

### Pregnancy

Adequate data is not available for the use of Td vaccine during pregnancy and therefore will not routinely be recommended in Alberta for pregnant women. However, use of this vaccine during pregnancy may be considered in consultation with your MOH based on the individual's risk of disease versus benefit of the vaccine.

### Lactation

Td vaccine can be administered to eligible breastfeeding women.

### Composition

Each 0.5 mL dose contains:

**Active Ingredients:**
- Tetanus toxoid - 5 Lf
- Diphtheria toxoid - 2 Lf

**Non-medical Ingredients:**
- **Excipients:**
  - Aluminum phosphate (adjuvant) – 1.5 mg
  - 2-phenoxyethanol – 0.6% v/v
  - Isotonic solution of sodium chloride in water for injection – q.s. 0.5 mL
- **Manufacturing residuals:**
  - Trace amounts of:
    - Formaldehyde

### Blood/Blood Products

Does not contain human blood or blood products.

### Bovine/Porcine Products

Bovine-derived products may be present in small amounts either as components of the culture media used to manufacture the vaccine or as a component of the final vaccine.

Porcine-derived products are used as raw materials in the early stages of the manufacturing process.

### Latex

The container closure system is free of latex (natural rubber).
<table>
<thead>
<tr>
<th><strong>Td Adsorbed®</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interchangeability</strong></td>
</tr>
</tbody>
</table>
| **Administration with Other Products** | • May be given at the same time as other inactivated vaccine using a separate needle and syringe for each vaccine.  
• The same limb may be used if necessary, but different sites on the limb must be chosen. |
| **Appearance** | Uniform cloudy suspension. |
| **Storage:** | • Store at +2°C to +8°C  
• Do not freeze  
• Do not use beyond the labeled expiry date  
• Store in original packaging when possible to protect from light |
| **Vaccine Code** | Td |
| **Antigen Code** | Tetanus – T  
Diphtheria – D |
| **Licensed for** | Individuals 7 years of age and older. |
| **Notes:** | • The combined Td vaccine was introduced into the Alberta Provincial program in 1980. |
| **Related Resources:** | • Tetanus and Diphtheria Information Sheet (104509) |